Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial

阿达木单抗 类风湿性关节炎 医学 相伴的 甲氨蝶呤 不利影响 临床终点 内科学 临床试验
作者
H. Tamai,Kei Ikeda,Toshiaki Miyamoto,Hiroaki Taguchi,Chang‐Fu Kuo,Kichul Shin,Shintaro Hirata,Yutaka Okano,Shinji Sato,Hidekata Yasuoka,Masataka Kuwana,Tomonori Ishii,Hideto Kameda,Toshihisa Kojima,Takehiro Taninaga,Masahiko Mori,Hideaki Miyagishi,Yasunori Sato,Wen‐Chan Tsai,Tsutomu Takeuchi
出处
期刊:The Lancet Rheumatology [Elsevier BV]
卷期号:5 (4): e215-e224 被引量:10
标识
DOI:10.1016/s2665-9913(23)00070-x
摘要

Summary

Background

Efficacy of combination therapy with methotrexate and biological disease-modifying antirheumatic drugs is well established in the management of patients with rheumatoid arthritis; however, the optimal dose of methotrexate to administer with a tumour necrosis factor inhibitor remains unclear. We aimed to clarify the efficacy and safety of adalimumab combined with reduced methotrexate dose compared with the maximum tolerated methotrexate dose in patients with rheumatoid arthritis and an inadequate response to methotrexate monotherapy.

Methods

In this open-label, randomised controlled trial, we recruited methotrexate-naive patients with rheumatoid arthritis and a disease duration of less than 2 years across 24 secondary or tertiary care hospitals across Japan, South Korea, and Taiwan. At initiation, methotrexate was given orally and increased to the maximum tolerated dose by week 12. Patients who did not achieve remission on the basis of the Simplified Disease Activity Index (SDAI) at week 24 were randomly assigned (1:1) to receive adalimumab (40 mg biweekly) combined with a continued maximum tolerated dose of methotrexate or adalimumab combined with a reduced dose of methotrexate. The primary endpoint was non-inferiority of adalimumab plus reduced-dose methotrexate to adalimumab plus maximal-dose methotrexate based on SDAI remission at week 48, assessed in the modified full-analysis set with a pre-specified non-inferiority margin of −15%, based on a two-sided 90% CI. Adverse events were assessed in the safety analysis set. This trial is registered with ClinicalTrials.gov, NCT03505008 and has been completed.

Findings

From April 18, 2018, to June 2, 2020, from 323 patients screened, 300 were enrolled, and 291 patients were included in the full analysis set. The mean age was 57·7 years (SD 15·2), 217 (75%) were female, 74 (25%) were male, and all patients were of Asian ethnicity. The mean SDAI at study enrolment was 26·5 (SD 12·4). 52 patients discontinued the study before week 24 or at week 24 before randomisation. At week 24, 105 (36%) of 291 patients achieved remission and continued methotrexate monotherapy through week 48. 134 (46%) did not achieve remission at week 24 and were randomly assigned to receive adalimumab plus the maximum tolerated dose of methotrexate (n=68) or adalimumab plus reduced-dose methotrexate (n=66). Remission at week 48 was achieved in 25 (38%) of 66 and 27 (44%) of 61 patients, respectively, with an adjusted risk difference of 6·4% (90% CI −7·0 to 19·8), which met the non-inferiority margin of −15%. Adverse events after week 24 tended to be more frequent in the maximum tolerated dose group than in the reduced-dose group (24 [35%] vs 13 [20%], p=0·054). Between week 24 and 48, there were 14 serious adverse events (6 in the methotrexate monotherapy group, 5 in the adalimumab plus maximal-dose methotrexate, and 3 in the adalimumab plus reduced-dose methotrexate group), and no deaths.

Interpretation

The MIRACLE study showed that the efficacy of adalimumab combined with reduced methotrexate dose was not inferior to that with the maximum tolerated methotrexate dose, with a tendency to a better safety profile.

Funding

Eisai.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
风吹麦浪发布了新的文献求助10
1秒前
2秒前
小净完成签到,获得积分10
3秒前
4秒前
5秒前
好人完成签到,获得积分10
6秒前
迷人的鱼完成签到,获得积分10
7秒前
stringz发布了新的文献求助30
8秒前
wentao发布了新的文献求助10
9秒前
10秒前
csf完成签到,获得积分10
11秒前
12秒前
12秒前
13秒前
13秒前
Jarvis完成签到,获得积分10
13秒前
15秒前
ayeben发布了新的文献求助10
15秒前
花深粥完成签到 ,获得积分10
16秒前
Shulei发布了新的文献求助10
16秒前
少爷完成签到,获得积分10
17秒前
实验狗发布了新的文献求助10
17秒前
李健的小迷弟的应助被chole采纳,获得10
17秒前
悦耳筮的应助被DW采纳,获得50
17秒前
17秒前
乐乐的应助被白rain采纳,获得10
17秒前
Nole的应助被薛定谔的猫爱摸鱼采纳,获得10
19秒前
863完成签到,获得积分10
19秒前
20秒前
20秒前
21秒前
星辰大海的应助被yydragen采纳,获得30
22秒前
cdercder的应助被缓慢的清涟采纳,获得10
23秒前
科研通AI65的应助被emmm采纳,获得10
24秒前
孜孜发布了新的文献求助10
25秒前
墨染完成签到 ,获得积分10
26秒前
DD发布了新的文献求助10
27秒前
28秒前
29秒前
打打的应助被DW采纳,获得10
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188339
求助须知:如何正确求助?哪些是违规求助? 9576114
关于积分的说明 21845532
捐赠科研通 7786371
什么是DOI,文献DOI怎么找? 3435279
关于科研通互助平台的介绍 2559581
邀请新用户注册赠送积分活动 2482182